Tichelli A, et al. - In this cohort study of 4065 European patients with 18 different second solid cancers (SSCs) after a stem cell transplant, researchers evaluated the outcome of patients with an SSC occurring after hematopoietic stem cell transplantation (HSCT) from the time of SSC diagnosis. Data reported that the 5-year age-standardized overall survival was 47%. Investigators found that the 5-year overall survival rate after SSC diagnosis was poor for pancreas, lung, hepatobiliary, esophageal, brain, and gastric cancers, with a median survival between 0.6 and 1 year. Overall, they concluded that the SSC outcome depends primarily on the type of second cancer.